Repligen posted solid growth and beat Wall Street's sales and adjusted earnings estimates.

Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.

Equity analysts in Manhattan have a difficult time imagining the logistics needs in Brazil. In this podcast, Motley Fool ...

Moving forward, Shift4 Payments has raised its guidance for key financial metrics, including its gross revenue less network ...

Total revenue for Q3 was $13.5 million, missing the $16.2 million analyst estimate. Operating expenses dropped by 24%, ...

Many or all of the products here are from our partners that compensate us. It’s how we make money. But our editorial ...

Lucid reported third-quarter financial results last week and had a net loss of $992 million. The company is trying to ...

The meat industry powerhouse reported a strong bottom-line recovery, with profitability rebounding in key segments.

Cronos Group ( CRON 12.13%) stock jumped 9.4% through 11:30 a.m. ET Tuesday after beating Wall Street forecasts for Q3 ...

Jefferies analyst Greg Konrad downgraded AeroVironment stock from buy to hold today. Shares of the military drone maker have ...

Arm Holdings ( ARM 0.04%) has been one of the biggest winners in the artificial intelligence (AI) boom. The company was late ...

The IT services specialist delivered stable revenue growth in its fiscal 2025 first quarter, but profits sank.